On March 20, 2024, Capstan Therapeutics, Inc. closed the transaction. The company has raised $175,000,000 in an oversubscribed round of funding led by returning investor, RA Capital Management, L.P. The transaction included participation from new investors, Forbion Capital Partners B.V., Johnson & Johnson Innovation - JJDC, Inc., Mubadala Investment Company PJSC, Perceptive Advisors LLC, Sofinnova Investment, Inc., returning investors, Alexandria Venture Investments, LLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Leaps by Bayer, Novartis Venture Funds, OrbiMed Advisors LLC, Pfizer Venture Investments LLC, Polaris Partners LLC and Vida Ventures Advisors, LLC. Nanna Luneborg of Forbion Capital Partners B.V. will join the board of directors.

The company has received $87,499,982 from 21 investors pursuant to Regulation D.